Bristol-Myers has new U.S. biologics capabilities ready to go

Bristol-Myers Squibb Devens, MA biologics facility
Bristol-Myers Squibb Devens, MA biologics facility

Bristol-Myers Squibb ($BMY) has been expanding its biologics production capacity as more and more of the drugs it is developing are large-molecule meds. One of those projects is now complete, adding about 200 jobs to a site in the U.S.

The company said this week it had completed its $280 million, 200,000-square-foot project in Devens, MA, adding a clinical manufacturing building and a biologics development building where it will design processes for its early production pipeline efforts. It said both are new capabilities for Devens, a site that had previously focused solely on large-scale, bulk biologics manufacturing.

“Biologics are increasingly important in the treatment of serious diseases and a rapidly growing part of our company’s pipeline of potential new therapies,” said Lou Schmukler, president of BMS global manufacturing and supply, in a release. “Bringing together biologics development and clinical and commercial manufacturing on one campus will help accelerate the development of these innovative medicines for patients worldwide.”

With its biologics pipeline in mind, the drugmaker is working on what it has described as essentially a twin of the Devens facilities, a 320,000-square-foot facility adjacent to a bulk manufacturing facility in Dublin. The project will have half a dozen 15,000-liter bioreactors and a purification area, as well as office and laboratory space. Between 350 and 400 workers will work at the plant when it is completed in 2019.

- here’s the announcement 

Related Articles: 
Bristol-Myers, Lilly expand biologics operations 
Bristol-Myers to build $900M biologics plant in Ireland